ipf-the data graphsIn the data published for the 3 studies ,as the weeks pass the graphs will be more in favor of prometic.For exemple,In the Impulsis2(nintedanib) at week 12 the FVC is +10 for PLI and -40 for nintenadib, so the gap is 50.
IF we stated that the fvc of PLI is stable at 10 and we add 8 weeks ,so 10 january 2017 , pli =10 but nintedanib is -50 on the graph that is already known, so the gap become 60.
As you added weeks the gap is bigger and bigger(maintaning PLI at 10)
The same thing for the other trial (ascend,perfenidone) .As the weeks pass , the graph is more and more in favor for PBI4050 .
When we will see the new graphs ,there will be no more question about the future of this fantastic product .